Loading…
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions. It also offers PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare organizations including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2026
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2026 | $481M | $29M | $2M | $54M | 0.7% | 14.5% | - |
| 2025 | $420M | $-26M | $-59M | $8M | -22.1% | 17.8% | - |
| 2024 | $356M | $-104M | $-137M | $-57M | -54.4% | 26.8% | - |
| 2023 | $281M | $-149M | $-176M | $-116M | -61.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total Revenue | 280.91 | 356.30 | 419.81 | 480.59 |
| Cost Of Revenue | 109.27 | 124.01 | 134.93 | 154.12 |
| Gross Profit | 171.64 | 232.29 | 284.88 | 326.47 |
| Operating Expense | 348.19 | 368.77 | 342.98 | 333.08 |
| Operating Income | -176.55 | -136.48 | -58.10 | -6.61 |
| EBITDA | -148.95 | -104 | -25.58 | 29.47 |
| EBIT | -174.25 | -133.49 | -53.46 | -1.99 |
| Pretax Income | -175.66 | -135.34 | -55.81 | -8.94 |
| Tax Provision | 0.48 | 1.54 | 2.72 | -11.25 |
| Net Income | -176.15 | -136.88 | -58.53 | 2.31 |
| Net Income Common Stockholders | -176.15 | -136.88 | -58.53 | 2.31 |
| Total Expenses | 457.46 | 492.78 | 477.91 | 487.20 |
| Interest Expense | 1.41 | 1.85 | 2.35 | 6.95 |
| Interest Income | 2.48 | 4.07 | 2.68 | 2.17 |
| Research And Development | 91.24 | 112.35 | 117.36 | 121.48 |
| Selling General And Administration | 231.65 | 226.93 | 197.73 | 180.15 |
| Normalized EBITDA | -148.95 | -102.88 | -25.58 | 29.97 |
| Normalized Income | -176.15 | -136 | -58.53 | 2.61 |
| Basic EPS | -3.36 | -2.51 | -1.02 | 0.04 |
| Diluted EPS | -3.36 | -2.51 | -1.02 | 0.04 |
| Tax Effect Of Unusual Items | 0 | -0.23 | 0 | -0.20 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 | 0.40 |
| Total Unusual Items | 0 | -1.12 | 0 | -0.50 |
| Total Unusual Items Excluding Goodwill | 0 | -1.12 | 0 | -0.50 |
| Net Income From Continuing Operation Net Minority Interest | -176.15 | -136.88 | -58.53 | 2.31 |
| Reconciled Depreciation | 25.30 | 29.49 | 27.89 | 31.45 |
| Reconciled Cost Of Revenue | 109.27 | 124.01 | 134.93 | 154.12 |
| Net Interest Income | 1.06 | 2.21 | 0.33 | -4.78 |
| Net Income From Continuing And Discontinued Operation | -176.15 | -136.88 | -58.53 | 2.31 |
| Total Operating Income As Reported | -176.55 | -136.48 | -58.10 | -6.61 |
| Diluted Average Shares | 52.44 | 54.56 | 57.59 | 61.49 |
| Basic Average Shares | 52.44 | 54.56 | 57.59 | 59.74 |
| Diluted NI Availto Com Stockholders | -176.15 | -136.88 | -58.53 | 2.31 |
| Otherunder Preferred Stock Dividend | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -176.15 | -136.88 | -58.53 | 2.31 |
| Net Income Continuous Operations | -176.15 | -136.88 | -58.53 | 2.31 |
| Other Income Expense | -0.17 | -1.07 | 1.96 | 2.45 |
| Other Non Operating Income Expenses | -0.17 | 0.04 | 1.96 | 2.95 |
| Special Income Charges | 0 | -1.12 | 0 | -0.50 |
| Other Special Charges | 0 | 1.12 | 0 | 0.50 |
| Net Non Operating Interest Income Expense | 1.06 | 2.21 | 0.33 | -4.78 |
| Interest Expense Non Operating | 1.41 | 1.85 | 2.35 | 6.95 |
| Interest Income Non Operating | 2.48 | 4.07 | 2.68 | 2.17 |
| Depreciation Amortization Depletion Income Statement | 25.30 | 29.49 | 27.89 | 31.45 |
| Depreciation And Amortization In Income Statement | 25.30 | 29.49 | 27.89 | 31.45 |
| Amortization | 7.32 | 11.90 | 13.70 | 18.48 |
| Amortization Of Intangibles Income Statement | 7.32 | 11.90 | 13.70 | 18.48 |
| Depreciation Income Statement | 17.99 | 17.58 | 14.18 | 12.97 |
| Selling And Marketing Expense | 151.26 | 147.01 | 121.13 | 100.24 |
| General And Administrative Expense | 80.38 | 79.93 | 76.60 | 79.90 |
| Other Gand A | 80.38 | 79.93 | 76.60 | 79.90 |
| Operating Revenue | 280.91 | 356.30 | 419.81 | 480.59 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Phreesia, Inc.this co. | PHR | $569M | 234.25↑ premium | 1.69 | 0.7% | 29.02 |
| CorMedix Inc. | CRMD | $591M | 3.67 | 1.46 | 40.2% | 3.38 |
| Prothena Corporation plc | PRTA | $585M | - | 2.09 | -87.0% | -1.56 |
| Anteris Technologies Global Corp. | AVR | $574M | - | -2950.00 | - | -6.11 |
| Zevra Therapeutics, Inc. | ZVRA | $572M | 7.16 |
| 3.56 |
| 53.8% |
| -2457.74 |
| NeuroPace, Inc. | NPCE | $562M | - | 29.17 | -112.8% | -35.19 |
| Rigel Pharmaceuticals, Inc. | RIGL | $540M | 1.50 | 1.37 | 93.8% | 3.43 |
| Embecta Corp. | EMBC | $536M | 5.72 | -0.84 | -14.6% | 6.16 |
| SI-BONE, Inc. | SIBN | $528M | - | 2.93 | -10.6% | -25.11 |
| Peer Median | - | 4.70 | 1.77 | -10.6% | -3.83 | |